Clinical Trial Update: Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma [NA]

View source ↗

Summary

Results posted for a study of NOVOTTF-200A in bevacizumab-naive subjects with recurrent grade III malignant astrocytoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma

Drugs mentioned

• NOVOTTF-200A

Snippet

Sponsor: Daniela A. Bota | Conditions: Astrocytoma, Grade III | NA | Status: COMPLETED | Results posted: 2025-07-16